Review of COVID-19 mRNA Vaccines: BNT162b2 and mRNA-1273
Open accessAbstract
The United States Food and Drug Administration recently issued emergency use authorization for 2 mRNA vaccines for preventing COVID-19 disease caused by SARS-CoV-2 virus infections. BNT162b2 from Pfizer-BioNTech and mRNA-1273 by Moderna are planned for use in mass-immunization programs to curb the pandemic. A brief overview of COVID-19 mRNA vaccines is provided, describing the SARS-CoV-2 RNA, how mRNA vaccines work and the advantages of mRNA over other vaccine platforms. The Pfizer-BioNTech collaboration journey to short-list mRNA vaccine candidates and finally selecting BNT162b2 based on safety data is outlined, followed by the Phase 3 study of BNT162b2 demonstrating 95% efficacy in preventing COVID-19 infections. Studies regarding mRNA-1273 (Moderna) are described, including extended immunogenicity data up to 119 days. The Phase 3 COVE study of mRNA-1273 eventually showed vaccine efficacy of 94.5%. Recommendations for future mRNA vaccine development are provided, including ongoing safety surveillance, evaluation in under-represented groups in previous studies and improving mRNA vaccine thermostability. Finally, further logistical considerations are required for manufacturing, storing, distribution and implementing mass vaccination programs to curb the pandemic.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Similar immune responses were observed among adolescents aged 12 to 17 after mRNA-1273.
“with similar immune responses among adolescents aged 12 to 17.410,412–414”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [413]
In a phase III clinical trial involving 30,420 people aged 18 or older, two doses of 100 μg mRNA-1273 with a 28-day interval had vaccine efficacy of 94.1%.
“In a phase III clinical trial involving 30,420 people, participants aged 18 or older were given two doses of 100 μg of mRNA-1273 with a 28-day interval, and vaccine efficacy was 94.1% (Table 5)”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [413]
Cites
A novel coronavirus from patients with pneumonia in China, 2019
Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001017 · Cited by 28,244 · see citing works
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592 · cited 1× · see citing works
“Although the duration of protection from a singledose remains uncertain, a second dose does not appear to confer much additional benefit for the vaccine recipients.(29) In the Moderna trial, 81 (0.”
BackgroundCryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897 · see citing works
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,237 · cited 1× · see citing works
“During the phase 1, dose-escalation trial, 45 healthy adults aged 18 to 55 years were administered 2 doses of 25 mg, 100 mg or 250 mg of mRNA-1273 28 days apart.(18) In this study, there was a dose-dependent antibody response; with increasing titers and serum-neutralizing activity after the second vaccination at the u…”
MethodRNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615 · see citing works
COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses
Sahin, U., Muik, A., Derhovanessian, E., Vogler, I., Kranz, L. M., Vormehr, M., Baum, A., Pascal, K., Quandt, J., Maurus, D., et al. (2020) · Nature · doi:10.1038/s41586-020-2814-7 · Cited by 1,977 · see citing works
SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness
Corbett, K. S., Edwards, D. K., Leist, S. R., Abiona, O. M., Boyoglu-Barnum, S., Gillespie, R. A., Himansu, S., Schäfer, A., Ziwawo, C. T., DiPiazza, A. T., et al. (2020) · Nature · doi:10.1038/s41586-020-2622-0 · Cited by 1,615 · see citing works
Mulligan, M. J., Lyke, K. E., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Raabe, V., Bailey, R., Swanson, K. A., et al. (2020) · doi:10.1101/2020.06.30.20142570 · Cited by 1,569 · see citing works
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
Anderson, E. J., Rouphael, N. G., Widge, A. T., Jackson, L. A., Roberts, P. C., Makhene, M., Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2028436 · Cited by 1,523 · see citing works
Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates
Corbett, K. S., Flynn, B., Foulds, K. E., Francica, J. R., Boyoglu-Barnum, S., Werner, A. P., Flach, B., O’Connell, S., Bock, K. W., Minai, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024671 · Cited by 1,066 · see citing works
Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination
Widge, A. T., Rouphael, N. G., Jackson, L. A., Anderson, E. J., Roberts, P. C., Makhene, M., Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2032195 · Cited by 722 · see citing works
A thermostable mRNA vaccine against COVID-19
Zhang, N.-N., Li, X.-F., Deng, Y.-Q., Zhao, H., Huang, Y.-J., Yang, G., Huang, W.-J., Gao, P., Zhou, C., Zhang, R.-R., et al. (2020) · Cell · doi:10.1016/j.cell.2020.07.024 · Cited by 671 · see citing works
mRNA vaccine delivery using lipid nanoparticles
Reichmuth, A. M., Oberli, M. A., Jaklenec, A., Langer, R., & Blankschtein, D. (2016) · Therapeutic Delivery · doi:10.4155/tde-2016-0006 · Cited by 624 · see citing works
Developing mRNA-vaccine technologies
Schlake, T., Thess, A., Fotin-Mleczek, M., & Kallen, K.-J. (2012) · RNA Biology · doi:10.4161/rna.22269 · Cited by 622 · see citing works
Addressing the Cold Reality of mRNA Vaccine Stability
Crommelin, D. J. A., Anchordoquy, T. J., Volkin, D. B., Jiskoot, W., & Mastrobattista, E. (2021) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2020.12.006 · Cited by 517 · see citing works
The COVID-19 Vaccine Race: Challenges and Opportunities in Vaccine Formulation
Wang, J., Peng, Y., Xu, H., Cui, Z., & Williams, R. O. (2020) · AAPS PharmSciTech · doi:10.1208/s12249-020-01744-7 · Cited by 327 · see citing works
Mechanism of action of mRNA-based vaccines
Iavarone, C., O’hagan, D. T., Yu, D., Delahaye, N. F., & Ulmer, J. B. (2017) · Expert Review of Vaccines · doi:10.1080/14760584.2017.1355245 · Cited by 234 · see citing works
Emergence of Drift Variants That May Affect COVID-19 Vaccine Development and Antibody Treatment
Koyama, T., Weeraratne, D., Snowdon, J. L., & Parida, L. (2020) · Pathogens · doi:10.3390/pathogens9050324 · Cited by 223 · see citing works
Li, M., Zhao, M., Fu, Y., Li, Y., Gong, T., Zhang, Z., & Sun, X. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.02.043 · Cited by 201 · see citing works
Brito, L. A., Kommareddy, S., Maione, D., Uematsu, Y., Giovani, C., Scorza, F. B., Otten, G. R., Yu, D. L., Mandl, C. W., Mason, P. W., et al. (2014) · Advances in genetics · doi:10.1016/bs.adgen.2014.10.005 · Cited by 182 · see citing works
Should We Mandate a COVID-19 Vaccine for Children?
Opel, D. J., Diekema, D. S., & Ross, L. F. (2021) · JAMA Pediatrics · doi:10.1001/jamapediatrics.2020.3019 · Cited by 124 · see citing works
Helfand, B., Webb, M. A., Gartaganis, S. L., Fuller, L., Kwon, C., & Inouye, S. K. (2020) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.5084 · Cited by 97 · see citing works
Planning for COVID-19 vaccines safety surveillance
Kochhar, S., & Salmon, D. A. (2020) · Vaccine · doi:10.1016/j.vaccine.2020.07.013 · Cited by 87 · see citing works
Tackling immunosenescence to improve COVID-19 outcomes and vaccine response in older adults
Cox, L. S., Bellantuono, I., Lord, J. M., Sapey, E., Mannick, J. B., Partridge, L., Gordon, A. L., Steves, C. J., & Witham, M. D. (2020) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(20)30011-8 · Cited by 73 · see citing works
Kinsella, C. M., Santos, P. D., Postigo-Hidalgo, I., Folgueiras-González, A., Passchier, T. C., Szillat, K. P., Akello, J. O., Álvarez‐Rodríguez, B., & Martí‐Carreras, J. (2020) · PLoS Pathogens · doi:10.1371/journal.ppat.1008902 · Cited by 33 · see citing works
Nour, N. M. (2020) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000003969 · Cited by 18 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Advances in COVID-19 mRNA vaccine development
Fang, E., Liu, X., Li, M., Zhang, Z., Song, L., Zhu, B., Wu, X., Liu, J., Zhao, D., & Li, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00950-y · Cited by 601 · see citing works
Jeong, M., Lee, Y., Park, J., Jung, H., & Lee, H. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114990 · Cited by 227 · see citing works
Bansal, S., Perincheri, S., Fleming, T. P., Poulson, C., Tiffany, B. R., Bremner, R. M., & Mohanakumar, T. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2100637 · Cited by 142 · see citing works
Two centuries of vaccination: historical and conceptual approach and future perspectives
Montero, D. A., Vidal, R. M., Velasco, J., Carreño, L. J., Torres, J. P., O., M. A. B., Tovar-Rosero, Y.-Y., Oñate, A. A., & O’Ryan, M. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1326154 · Cited by 160 · see citing works
Current Developments and Challenges of mRNA Vaccines
Chen, J., Chen, J., & Xu, Q. (2022) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-110220-031722 · Cited by 106 · see citing works
Hammel, M., Fan, Y., Sarode, A., Byrnes, A. E., Zang, N., Kou, P., Nagapudi, K., Leung, D., Hoogenraad, C. C., Chen, T., et al. (2023) · ACS Nano · doi:10.1021/acsnano.3c01186 · Cited by 107 · see citing works
Lipid-Based Nanoformulations for Drug Delivery: An Ongoing Perspective
Rehman, M., Tahir, N., Sohail, M. F., Qadri, M. U., Duarte, S. O. D., Brandão, P., Esteves, T., Javed, I., & Fonte, P. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16111376 · Cited by 104 · see citing works
mRNA vaccine sequence and structure design and optimization: Advances and challenges
Jin, L., Zhou, Y., Zhang, S., & Chen, S. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.108015 · Cited by 85 · see citing works
Sarode, A., Fan, Y., Byrnes, A. E., Hammel, M., Hura, G. L., Fu, Y., Kou, P., Hu, C., Hinz, F. I., Roberts, J., et al. (2022) · Nanoscale Advances · doi:10.1039/d1na00712b · Cited by 76 · see citing works
Lipid Nanoparticles as Promising Carriers for mRNA Vaccines for Viral Lung Infections
Asr, M. H., Dayani, F., Segherloo, F. S., Kamedi, A., Neill, A. O., MacLoughlin, R. J., & Doroudian, M. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041127 · Cited by 73 · see citing works
The mRNA Vaccine Revolution: COVID-19 Has Launched the Future of Vaccinology
Ye, Z., Harmon, J., Ni, W., Li, Y., Wich, D., & Xu, Q. (2023) · ACS Nano · doi:10.1021/acsnano.2c12584 · Cited by 71 · see citing works
Recent Developments in Vaccine Design: From Live Vaccines to Recombinant Toxin Vaccines
Gupta, S., & Pellett, S. (2023) · Toxins · doi:10.3390/toxins15090563 · Cited by 77 · see citing works
Nanotechnologies in Delivery of DNA and mRNA Vaccines to the Nasal and Pulmonary Mucosa
Tang, J., Cai, L., Xu, C., Sun, S., Liu, Y., Rosenecker, J., & Guan, S. (2022) · Nanomaterials · doi:10.3390/nano12020226 · Cited by 54 · see citing works
Nano-formulations in disease therapy: designs, advances, challenges, and future directions
Shi, Y., Li, X., Li, Z., Sun, J., Gao, T., Wei, G., & Guo, Q. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03442-7 · Cited by 56 · see citing works
Design Strategies for and Stability of mRNA–Lipid Nanoparticle COVID-19 Vaccines
Liu, T., Tian, Y., Zheng, A., & Cui, C. (2022) · Polymers · doi:10.3390/polym14194195 · Cited by 52 · see citing works
mRNA vaccines in the prevention and treatment of diseases
Gu, Y., Duan, J., Yang, N., Yang, Y., & Zhao, X. (2022) · MedComm · doi:10.1002/mco2.167 · Cited by 51 · see citing works
Characterization of mRNA therapeutics
Guimaraes, G. J., Kim, J., & Bartlett, M. G. (2023) · Mass Spectrometry Reviews · doi:10.1002/mas.21856 · Cited by 48 · see citing works
Pharmacovigilance and Its Importance for Primary Health Care Professionals
Hamid, A. A. A., Rahim, R., & Teo, S. P. (2022) · Korean Journal of Family Medicine · doi:10.4082/kjfm.21.0193 · Cited by 46 · see citing works
Self-citationCardiovascular consequences of viral infections: from COVID to other viral diseases
Schultheiß, H., Baumeier, C., Pietsch, H., Bock, C. –., Poller, W. C., & Escher, F. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab315 · Cited by 46 · see citing works
On the mechanism of tissue-selective gene delivery by lipid nanoparticles
Kimura, S., & Harashima, H. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.03.052 · Cited by 46 · see citing works
Research progress on the quality control of mRNA vaccines
Hu, C., Bai, Y., Liu, J., Wang, Y., He, Q., Zhang, X., Cheng, F., Xu, M., Mao, Q., & Liang, Z. (2024) · Expert Review of Vaccines · doi:10.1080/14760584.2024.2354251 · Cited by 45 · see citing works
Effects of PEG antibodies on in vivo performance of LNP-mRNA vaccines
Yang, M. J., Zhang, Z., Jin, P., Jiang, K., Xu, Y., Pan, F., Tian, K., Yuan, Z., Liu, X., Fu, J., et al. (2023) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2023.123695 · Cited by 43 · see citing works
Prophylactic and therapeutic vaccine development: advancements and challenges
Weerarathna, I. N., Doelakeh, E. S., Kiwanuka, L., Kumar, P., & Arora, S. (2024) · Molecular Biomedicine · doi:10.1186/s43556-024-00222-x · Cited by 43 · see citing works
Kumar, M., Dogra, R., & Mandal, U. K. (2022) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2022.103533 · Cited by 37 · see citing works
Zhao, Y., & Wang, H. (2025) · Briefings in Bioinformatics · doi:10.1093/bib/bbaf263 · Cited by 40 · see citing works
Byrnes, A. E., Domínguez, S. L., Yen, C., Laufer, B. I., Foreman, O., Reichelt, M., Lin, H., Sagolla, M. S., Hötzel, K., Ngu, H., et al. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.05.005 · Cited by 35 · see citing works
Zwitterionic materials for nucleic acid delivery and therapeutic applications
He, S., & Liu, S. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.12.017 · Cited by 33 · see citing works
Izumo, T., Kuse, N., Awano, N., Tone, M., Sakamoto, K., Takada, K., Muto, Y., Fujimoto, K., Saiki, A., Ito, Y., et al. (2021) · Respiratory Investigation · doi:10.1016/j.resinv.2021.06.003 · Cited by 31 · see citing works
Delivery of nucleic acids using nanomaterials
Qin, Y., Ou, L., Zha, L., Zeng, Y., & Li, L. (2023) · Molecular Biomedicine · doi:10.1186/s43556-023-00160-0 · Cited by 33 · see citing works
Nanoparticles and Antiviral Vaccines
Liu, S., Hu, M., Liu, X., Liu, X., Chen, T., Zhu, Y., Liang, T., Xiao, S., Li, P., & Ma, X. (2023) · Vaccines · doi:10.3390/vaccines12010030 · Cited by 33 · see citing works
RNA Therapeutics: Delivery Problems and Solutions—A Review
Pozdniakova, N. V., Generalov, E. A., Shevelev, A. B., & Tarasova, O. A. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17101305 · Cited by 32 · see citing works
mRNA vaccines: A novel weapon to control infectious diseases
Tian, Y., Deng, Z., & Yang, P. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.1008684 · Cited by 28 · see citing works
Elbaz, M., Ad-El, N., Chulanova, Y., Brier, D., Goldsmith, M., Bismuth, M., Brosque, A., Sher, D., Gutkin, A., Bar-On, D., et al. (2025) · doi:10.1101/2025.01.23.634427 · Cited by 28 · see citing works
Wu, Y., Zhang, H., Meng, L., Li, F., & Yu, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.906457 · Cited by 28 · see citing works
The Role of Cellular Immunity in the Protective Efficacy of the SARS-CoV-2 Vaccines
Sun, Z., Wu, T., Xie, H., Li, Y., Zhang, J., Su, X., & Qi, H. (2022) · Vaccines · doi:10.3390/vaccines10071103 · Cited by 29 · see citing works
Schreckenberg, R., Woitasky, N., Itani, N., Czech, L., Ferdinandy, P., & Schulz, R. (2023) · British Journal of Pharmacology · doi:10.1111/bph.16262 · Cited by 30 · see citing works
Hajjo, R., Sabbah, D. A., & Tropsha, A. (2022) · Pathogens · doi:10.3390/pathogens11070743 · Cited by 26 · see citing works
Development and application of ribonucleic acid therapy strategies against COVID-19
Lin, N., Liu, M., Gou, Y., Yang, Y., He, B., & Huang, J. H. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.72706 · Cited by 26 · see citing works
Hurdles to healing: Overcoming cellular barriers for viral and nonviral gene therapy
Honrath, S., Burger, M., & Leroux, J. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.125470 · Cited by 28 · see citing works
Review: N1-methyl-pseudouridine (m1Ψ): Friend or foe of cancer?
Rubio‐Casillas, A., Cowley, D., Raszek, M., Uversky, V. N., & Redwan, E. M. M. M. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.131427 · Cited by 24 · see citing works
Advances in the study of LNPs for mRNA delivery and clinical applications
Wang, B., Shen, B., Xiang, W., & Shen, H. (2024) · Virus Genes · doi:10.1007/s11262-024-02102-6 · Cited by 21 · see citing works
Non‐Viral Gene Delivery Systems: Current Advances and Therapeutic Applications
Wang, F., Liang, L., Wang, C., Zhang, C., Ye, Y., Dou, L., Shi, L., Zhou, D., & Sun, X. (2025) · Chemistry - An Asian Journal · doi:10.1002/asia.202500684 · Cited by 21 · see citing works
Effect of Antigen Structure in Subunit Vaccine Nanoparticles on Humoral Immune Responses
Park, J., & Champion, J. A. (2023) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.2c01516 · Cited by 21 · see citing works
Hajjo, R., Momani, E., Sabbah, D. A., Baker, N., & Tropsha, A. (2023) · npj Vaccines · doi:10.1038/s41541-023-00719-6 · Cited by 19 · see citing works
Napuri, N., Curcio, D., Swerdlow, D. L., & Srivastava, A. K. (2022) · Infectious Diseases and Therapy · doi:10.1007/s40121-022-00648-2 · Cited by 17 · see citing works
Zhu, D., Chen, W., Lin, W., Li, Y., & Liu, X. (2021) · Biomedical Materials · doi:10.1088/1748-605x/ac0a8f · Cited by 17 · see citing works
Silver and Silver Nanoparticles for the Potential Treatment of COVID-19: A Review
Arjun, P. N. J., Sankar, B., Shankar, K. V., Kulkarni, N. V., Sivasankaran, S., & Shankar, B. (2022) · Coatings · doi:10.3390/coatings12111679 · Cited by 17 · see citing works
Wang, Z., Tian, C., Zhu, J., Wang, S., Ao, X., He, Y., Chen, H., Liao, X., Kong, D., Zhou, Y.-F., et al. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03156-w · Cited by 18 · see citing works
Nakamura, K., Aihara, K., & Ishida, T. (2022) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b21-01016 · Cited by 16 · see citing works
RNA vaccines: The dawn of a new age for tuberculosis?
Li, J., Liu, D., Li, X., Wei, J., Du, W., Zhao, A., & Xu, M. (2025) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2025.2469333 · Cited by 18 · see citing works
A brief review of mRNA therapeutics and delivery for bone tissue engineering
Rajendran, A. K., Amirthalingam, S., & Hwang, N. S.-Y. (2022) · RSC Advances · doi:10.1039/d2ra00713d · Cited by 16 · see citing works
Li, W., Wang, T., Chen, J., Guo, M., Ling, L., & Higuchi, A. (2024) · Regenerative medicine and dentistry. · doi:10.53941/rmd.2024.100003 · Cited by 15 · see citing works
Xu, Z., Song, J. H., Zhang, H., Wei, Z., Wei, D., Guangyu, Y., Jacques Demongeot, A., & Zeng, Q. (2024) · Scientific Reports · doi:10.1038/s41598-024-74221-x · Cited by 15 · see citing works
Mohammadi, G., Koranni, Z. S., & Jebali, A. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108231 · Cited by 15 · see citing works
Mantri, P., Juneja, B., Henderson, S., Koufos, E., Moon, Y., Dayeh, D. M., Grandi, D. D., Fu, Y., Muthusamy, K., Ihnat, P. M., et al. (2024) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2024.116352 · Cited by 16 · see citing works
Choi, D., Khan, N., Montermini, L., Tawil, N., Meehan, B., Kim, D., Roth, F. P., Divangahi, M., & Rak, J. W. (2022) · Journal of Extracellular Biology · doi:10.1002/jex2.58 · Cited by 14 · see citing works
Agent-based model of the impact of higher influenza vaccine efficacy on seasonal influenza burden
Krauland, M. G., Zimmerman, R. K., Williams, K. V., Raviotta, J. M., Harrison, L. H., Williams, J. V., & Roberts, M. S. (2022) · Vaccine X · doi:10.1016/j.jvacx.2022.100249 · Cited by 12 · see citing works
Wang, S., Guo, B., Wang, H., & Yang, F. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.105547 · Cited by 13 · see citing works
Strategies for Organ‐Targeted mRNA Delivery by Lipid Nanoparticles
Liao, H., Liao, J. P., Zeng, L., Cao, X., Fan, H., & Chen, J. (2024) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.2004 · Cited by 13 · see citing works
Ammad, M., Javed, Z., Sadia, H., Ahmed, R., Akbar, A. U., Nadeem, T., Călina, D. C., & Sharifi‐Rad, J. (2024) · Medical Oncology · doi:10.1007/s12032-024-02534-y · Cited by 13 · see citing works
Breaking barriers: Smart vaccine platforms for cancer immunomodulation
Gomari, M. M., Ghantabpour, T., Pourgholam, N., Rostami, N., Hatfield, S. M., Namazifar, F., Abkhiz, S., Eslami, S. S., Ramezanpour, M., Darestanifarahani, M., et al. (2025) · 癌症：英文版 · doi:10.1002/cac2.70002 · Cited by 13 · see citing works
Microneedle‐Enabled Breakthroughs in Nucleic Acid Therapeutics
Wu, P., Zhang, T., Zhao, D., Xie, Y., Huang, D., Li, Z., & Huang, Y. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202501015 · Cited by 13 · see citing works
Potential roles of mesenchymal stem cells and their exosomes in the treatment of COVID-19
Cheng, X., Jiang, M., Long, L., & Meng, J. (2021) · Frontiers in Bioscience-Landmark · doi:10.52586/4999 · Cited by 13 · see citing works
Application of Nanoparticles in Tumour Targeted Drug Delivery and Vaccine
Tu, Y., Yao, Z., Yang, W., Tao, S., Li, B., Wang, Y., Su, Z., & Li, S. (2022) · Frontiers in Nanotechnology · doi:10.3389/fnano.2022.948705 · Cited by 12 · see citing works
COVID-19 vaccination and liver disease
Ozaka, S., Kobayashi, T., Mizukami, K., & Murakami, K. (2022) · World Journal of Gastroenterology · doi:10.3748/wjg.v28.i48.6791 · Cited by 13 · see citing works
Recent research advances in the development of Dabie Banda virus vaccines
Yu, C., Lin, Y., Dai, Y., Wu, B., Qi, Z., & Qian, X. (2024) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0012411 · Cited by 12 · see citing works
Mossadeq, S., Shah, R., Shah, V., & Bagul, M. (2022) · AAPS PharmSciTech · doi:10.1208/s12249-022-02455-x · Cited by 12 · see citing works
Practical Considerations for Next-Generation Adjuvant Development and Translation
Lykins, W. R., & Fox, C. B. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071850 · Cited by 11 · see citing works
Current Development of Therapeutic Vaccines in Lung Cancer
Banda, J. S. F., Gangane, S., Raza, F., & Massarelli, E. (2025) · Vaccines · doi:10.3390/vaccines13020185 · Cited by 11 · see citing works
Kimura, S., Okada, K., Matsubara, N., Lyu, F., Tsutsumi, S., Kimura, Y., Hashiya, F., Inagaki, M., Abe, N., & Abe, H. (2025) · RSC Medicinal Chemistry · doi:10.1039/d5md00084j · Cited by 11 · see citing works
A self-amplifying mRNA vaccine expressing PRV gD induces robust immunity against virulent mutants
Ling, T., Zhang, X., Huan-huan, L., Ya-Ting, Z., Ya-mei, L., RongLi, G., DAMIANI, A. M., Sai-Sai, C., Chuan-jian, Z., Rui, D., et al. (2025) · npj Vaccines · doi:10.1038/s41541-025-01251-5 · Cited by 13 · see citing works
Zhang, M., Van, L. M., & Amiji, M. M. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102686 · Cited by 11 · see citing works
Fang, L., Gu, W.-T., Li, R.-X., Chen, C., Cai, S.-M., Luozhong, S., Chen, M., Hsu, A., Tsai, Y.-C., Londhe, K., et al. (2024) · ACS Nano · doi:10.1021/acsnano.4c07530 · Cited by 12 · see citing works
Matar, R., Mansour, R., Nakanishi, H., Smayra, K., Haddad, J. E., Vankayalapati, D. K., Daniel, R. S., Tosovic, D., Than, C. A., & Yamani, M. H. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11154521 · Cited by 10 · see citing works
A Brief Review on Medicinal Plants-At-Arms against COVID-19
Srivastava, S., He, F., Huang, Y., Niu, M., Adholeya, A., & Peng, W. K. (2023) · Interdisciplinary Perspectives on Infectious Diseases · doi:10.1155/2023/7598307 · Cited by 10 · see citing works
Sander, I., Kespohl, S., Zahradnik, E., Göcke, P., Hosbach, I., Herrmann, B. L., Brüning, T., & Raulf, M. (2022) · Clinical & Translational Immunology · doi:10.1002/cti2.1369 · Cited by 9 · see citing works
Li, J., Huang, F., Ma, Q., Guo, W., Feng, K., Huang, T., & Cai, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1131051 · Cited by 10 · see citing works
Evaluation of the immunoprotective effects of porcine deltacoronavirus subunit vaccines
Yu, R., Zhang, L., Zhou, P., Zhang, Z., Liu, X., Wang, Y., Guo, H., Li, P., & Liu, X. (2023) · Virology · doi:10.1016/j.virol.2023.109955 · Cited by 9 · see citing works
Chen, C., Chen, C., Cao, L., Fang, J., & Xiao, J. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112022 · Cited by 9 · see citing works
From Sequence to System: Enhancing IVT mRNA Vaccine Effectiveness through Cutting-Edge Technologies
Xu, L., Li, C., Liao, R., Xiao, Q., Wang, X., Zhao, Z., Zhang, W., Ding, X., Cao, Y., Cai, L., et al. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c00863 · Cited by 10 · see citing works
Nail psoriasis: a rare mRNA COVID ‐19 vaccine reaction
Lamberti, A., Lora, V., Graceffa, D., Bonifati, C., & Cota, C. (2022) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.18255 · Cited by 9 · see citing works
Developing Vaccines in Pancreatic Adenocarcinoma: Trials and Tribulations
Phan, T. X., Fan, D., & Melstrom, L. G. (2024) · Current Oncology · doi:10.3390/curroncol31090361 · Cited by 9 · see citing works
Cell-specific mRNA delivery via nanobody-functionalized lipid nanoparticles
Chen, L., der Weken, H. V., Zwaenepoel, O., Okkelman, I. A., Aelvoet, J., Denberghe, E. V., Gettemans, J., Dmitriev, R. I., Geest, B. G. D., Cox, E., et al. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114365 · Cited by 8 · see citing works
Zhou, C., Liu, Z., Peng, Z.-R., Luo, X.-Y., Zhang, X., Zhang, J. G., Zhang, L., Chen, W., & Yang, Y. (2025) · Gut Microbes · doi:10.1080/19490976.2025.2484386 · Cited by 7 · see citing works
Tscherne, A., Kalodimou, G., Kupke, A., Rohde, C., Freudenstein, A., Jany, S., Kumar, S., Sutter, G., Krähling, V., Becker, S., et al. (2024) · Vaccines · doi:10.3390/vaccines12121316 · Cited by 7 · see citing works
Thakur, A. (2023) · Life · doi:10.3390/life13030840 · Cited by 7 · see citing works
A Yellow Fever 17D Virus Replicon-Based Vaccine Platform for Emerging Coronaviruses
Oreshkova, N., Myeni, S. K., Mishra, N., Albulescu, I. C., Dalebout, T. J., Snijder, E. J., Bredenbeek, P. J., Dallmeier, K., & Kikkert, M. (2021) · Vaccines · doi:10.3390/vaccines9121492 · Cited by 7 · see citing works
Real world pharmacovigilance study of antineoplastic drug related vitiligo risks
Yang, Y., Xie, H., Li, D., Jia, Y., Cui, B., Zou, J., & Xiao, Z. (2025) · Scientific Reports · doi:10.1038/s41598-025-06314-0 · Cited by 6 · see citing works
Engineering Delivery Technologies for Optimizing mRNA Vaccines
Gu, T., Yan, X., & Liu, S. (2025) · ACS Nano Medicine · doi:10.1021/acsnanomed.5c00032 · Cited by 6 · see citing works
Abue, M., Mochizuki, M., Shibuya‐Takahashi, R., Ota, K., Wakui, Y., Iwai, W., Kusaka, J., Saito, M., Suzuki, S., Sato, I., et al. (2025) · Cancers · doi:10.3390/cancers17122006 · Cited by 8 · see citing works
Functional profiling of Covid 19 vaccine candidate by flow virometry
Prout, A., Rustandi, R. R., Tubbs, C. M., Winters, M. A., McKenna, P. M., & Vlasak, J. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.08.006 · Cited by 6 · see citing works
Adaptive immune response to BNT162b2 mRNA vaccine in immunocompromised adolescent patients
Bader, G., Itan, M., Edry‐Botzer, L., Cohen, H., Haskin, O., Mozer‐Glassberg, Y., Harel, L., Munitz, A., Marcus, N., & Gerlic, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1131965 · Cited by 5 · see citing works
Oral non-viral gene delivery platforms for therapeutic applications
Ghaemi, A., Azghandi, M. V., Abnous, K., Taghdisi, S. M., Ramezani, M., & Alibolandi, M. (2023) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2023.123198 · Cited by 6 · see citing works
Makhijani, S., Elossaily, G. M., Rojekar, S. V., & Ingle, R. G. (2024) · Pharmaceutical Development and Technology · doi:10.1080/10837450.2024.2361656 · Cited by 6 · see citing works
Association between Adverse Reactions to the First and Second Doses of COVID-19 Vaccine
Goda, K., Kenzaka, T., Yahata, S., Okayama, M., & Nishisaki, H. (2022) · Vaccines · doi:10.3390/vaccines10081232 · Cited by 6 · see citing works
Challenges and Opportunities Used in RNA-Based Therapeutics
Chauhan, P., Tiwari, I., & Sharma, N. K. (2025) · Springer eBooks · doi:10.1007/978-981-96-3456-9_10 · Cited by 5 · see citing works
The stability landscape of mRNA vaccines: challenges and mitigation strategies
Zhong, L., Tao, L., Zhai, Z., Liao, L., Shi, C., Yao, S., & Liu, X. (2026) · Vaccine · doi:10.1016/j.vaccine.2026.128515 · Cited by 6 · see citing works
Zhang, Y., Béland, L., Roussel, S., Bertrand, N., Hébert, S. S., & Vallières, L. (2024) · Journal of Leukocyte Biology · doi:10.1093/jleuko/qiae059 · Cited by 5 · see citing works
Promising RNA-based therapies for viral infections, genetic disorders, and cancer
Musa, D. A., Raji, M. O., Sikiru, A. B., Aremu, H. K., & Aigboeghian, E. A. (2024) · Academia molecular biology and genomics. · doi:10.20935/acadmolbiogen7329 · Cited by 7 · see citing works
Wang, C., Tang, X., Jiang, C., Zhang, Y., Han, B., Sun, Y., Guo, J., Peng, H., Wang, Z., Wang, Y., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1530736 · Cited by 5 · see citing works
- Authors
- Teo, S. P.
- Affiliations
- Raja Isteri Pengiran Anak Saleha Hospital (BN)
- Corresponding author
- Teo, Shyh Poh
- ORCID
- Teo, Shyh Poh
- Venue
- Journal of Pharmacy Practice
- Publisher
- SAGE Publications
- Published
- 2021-04-12
- Volume
- 35
- Issue
- 6
- Pages
- 947-951
- ISSN
- 0897-1900 (ISSN-L)
- 1531-1937
- OpenAlex
- W3154719862
- Cited by
- 191
- References
- 26
- Citations by year
- 2026: 24 · 2025: 42 · 2024: 35 · 2023: 39 · 2022: 37 · 2021: 14
- FWCI
- 3.65
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Pharmacy Practice (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- COVID-19 mRNA vaccine, BNT162b2, mRNA-1273, SARS-CoV-2, vaccine development, vaccine efficacy, immunogenicity, vaccine safety, emergency use authorization, vaccine thermostability, underrepresented groups
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, 2019-nCoV Vaccine mRNA-1273, Humans, RNA, Viral, United States, Viral Vaccines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
